For example, the PD-1 inhibitor atezolizumab was more effective in improving urothelial carcinoma patient outcomes for those with PD-L1-expressing tumors versus participants with PD-L1-negative tumors [187], whereas pembrolizumab improved patient outcome regardless of PD-L1 status [188]. Here, CD274 is linked to urothelial carcinoma.